

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	RAKOCZI, Ferenc, <i>et al.</i>) Examiner:	CHOI, Frank I.
)	
Serial No.:	10/565,520) Art Unit:	1616
)	
US Filing or 371C Date:	July 28, 2004) Attay Docket:	H-33238A
)	
For:	ORGANIC COMPOUNDS) Confirmation No.:	2957

INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

1. This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

2. Pursuant to 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

3. Pursuant to 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed as an admission that the information cited in this Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

4. The references listed on the enclosed Form PTO-1449 are being submitted because they were cited in the equivalent case in Japan (Japanese Patent Application No. 2006-521520). All of the references cited in the equivalent case in Japan are Japanese patents or applications. Pursuant to 37 C.F.R. § 1.98(a)(3), the status of the documents, as well as

submitted English-language equivalents of the documents listed in the enclosed Form PTO-1449 is summarized below:


- JP Associate Memo, listed as a Foreign Patent Document, dated March 9, 2010, was sent by the associate handling the equivalent Japanese case, and sets forth the references cited by the Japanese patent office, along with brief remarks on the references,
- WO9422299, listed as a Foreign Patent Document, is believed to be an English-language equivalent of JP8508287, cited as D1 in the JP Associate Memo,
- US 4,855,133, listed as a US Patent (and already cited by Examiner Choi in the March 24, 2010 Office Action), is believed to be an English-language equivalent of JP62042903, cited as D2 in the JP Associate Memo,
- US 4,122,165, listed as a US Patent, is believed to be an English-language equivalent of JP54044020, cited as D3 in the JP Associate Memo,
- Derwent Abstract 07832C/05, listed as a Foreign Patent Document, is believed to be an English-language equivalent of the abstract of JP55015465, cited as D4 in the JP Associate Memo,
- US 4,205,066, listed as a US Patent (already made of record in the IDS filed January 23, 2006), is believed to be an English-language equivalent of JP54067032, cited as D5 in the JP Associate Memo,
- Abstract JP8056542, listed as a Foreign Patent Document, is believed to be an English-language equivalent of the abstract of JP8056542, cited as D6 in the JP Associate Memo,
- EP 431468, listed as a Foreign Patent Document, is believed to be an English-language equivalent of JP3232804, cited as D7 in the JP Associate Memo,
- US 2001/0046986, listed as a US Patent Application Publication (and already cited by Examiner Choi in March 24, 2010 Office Action), is believed to be an English-language equivalent of JP2001302408, cited as D8 in the JP Associate Memo, and
- Abstract JP2002275404, listed as a Foreign Patent Document, is believed to be an English-language equivalent of the abstract of JP2002275404, cited as D9 in the JP Associate Memo.

5. Pursuant to 37 C.F.R. § 1.97(c)(2), the Commissioner is hereby authorized to charge the current \$180.00 fee under 37 C.F.R. § 1.17(p).

The Commissioner is hereby authorized to charge any additional fees required for consideration of this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-4389, identifying our Docket No. H-33238A.

Respectfully submitted,

Date: 14 May 2010

By: 
Todd Sladek
Registration No. 53,768

NOVARTIS ANIMAL HEALTH US, INC.
3200 Northline Avenue, Suite 300
Greensboro, NC 27408

Office: (336) 387-1601
E-mail: todd.sladek@novartis.com